Therapies targeting immune checkpoints have become an established treatment option in oncology. However, due to the generalised immunomodulating effects of the immune checkpoint inhibitors (ICIs), a wide range of immune-related adverse events (irAEs) has been described. Most reported irAEs are based on clinical trial data of patients who received several doses of ICI monotherapy or combined with chemotherapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
NCI common Terminology criteria for adverse events (CTCAE), version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Immune-related adverse events associated with immune checkpoint blockade.N Engl J Med. 2018; 378: 158-168
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review.Eur J Canc. 2016; : 54 139-148https://doi.org/10.1016/j.ejca.2015.11.016
- Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma.Hematol Oncol Stem Cell Ther. 2020; https://doi.org/10.1016/j.hemonc.2020.04.006
- Diabetic ketoacidosis induced by a single dose of pembrolizumab.Am J Emerg Med. 2019; 37: 376.e1-376.e2https://doi.org/10.1016/j.ajem.2018.10.040
- Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.Haematologica. 2018; 103: e318-e321https://doi.org/10.3324/haematol.2017.185777
Published online: April 20, 2021
Accepted: January 29, 2021
Received: January 18, 2021
© 2021 Elsevier Ltd. All rights reserved.